| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/22/2006 | CN1750810A A low dose corticosteroid composition |
| 03/22/2006 | CN1750809A Fast dissolving orally consumable films containing pharmaceutically active agents |
| 03/22/2006 | CN1750183A Double function magnetic fluid and its preparing method |
| 03/22/2006 | CN1748671A Slow releasing injection containing anti-mitosis medicine |
| 03/22/2006 | CN1246047C A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same |
| 03/22/2006 | CN1246040C Process to make a sustained release formulation |
| 03/22/2006 | CN1246039C Moxilfloxacin formulation containing common salt |
| 03/22/2006 | CN1246038C Systemic delivery of oral vaccines of botulinus toxin |
| 03/22/2006 | CN1246035C Medicine composition of macrolides or cyclosporin and polyoxide saturated hydoxy fatty acid |
| 03/22/2006 | CN1245994C Use of salivary lactobacillus |
| 03/22/2006 | CN1245991C Shark meat extract |
| 03/22/2006 | CN1245985C Compositions containing ascorbic acid phosphoric acid esters |
| 03/22/2006 | CN1245977C Liposome anti-neoplastic drugs and uses thereof |
| 03/22/2006 | CN1245976C Pharmaceutical formulations in hydroxypropylmenthyl cellulose capsules |
| 03/22/2006 | CN1245962C Novel process |
| 03/22/2006 | CN1245961C Ultraviolet shielding adhesive preparation |
| 03/22/2006 | CN1245960C Non-oral preparation having three-layer structure |
| 03/22/2006 | CN1245958C Controlled release hydroxy-ketone |
| 03/22/2006 | CN1245955C Thermoprotected microparticle compositions and process for terminal steam sterilization thereof |
| 03/22/2006 | CN1245875C Solutions of alkoxylated alkanol amide surfactants and antimicrobial compounds |
| 03/21/2006 | USRE39030 Fluoxetine enteric pellets and methods for their preparation and use |
| 03/21/2006 | US7015352 Capable of permeating a desired biological compartment and releasing a biologically active molecule in active form to effect a therapeutic functional change in the compartment to which it is introduced |
| 03/21/2006 | US7015306 Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes |
| 03/21/2006 | US7015245 Formulation to enhance antioxidant potency of Vitamin E |
| 03/21/2006 | US7015232 Stablizer retards cyclization and discoloration of quinapril |
| 03/21/2006 | US7015202 Adjust migration of monocytes, lymphocytes or interleukins; controllinginfections |
| 03/21/2006 | US7015200 Carbohydrates conjugated to optionally protected 4-hydroxybutyric acid; enhance the uptake of the drug and allows effective drug delivery to treat GHB-treatable disorders such as sleep disorders or drug withdrawal |
| 03/21/2006 | US7014871 Iodine preparation composition |
| 03/21/2006 | US7014869 Rapid dehydration of proteins |
| 03/21/2006 | US7014867 Tablet comprising cetirizine and pseudoephedrine |
| 03/21/2006 | US7014866 High dose solid unit oral pharmaceutical dosage form of amorphous nelfinavir mesylate and process for making same |
| 03/21/2006 | US7014862 Chewable compositions containing a gel-forming extract of psyllium |
| 03/21/2006 | US7014857 Anti-sepsis conjugate vaccine |
| 03/21/2006 | US7014856 for stimulating or enhancing production of an antibody which recognizes a ganglioside; comprises a ganglioside or oligosaccharide portion conjugated to an immunogenic protein with a carrier and/or vehicle; cancer treatment |
| 03/21/2006 | US7014855 inducing an immune response against a peptide component of an amyloid deposit; active administration of an immunogen or passive administration of an antibody or an active fragment or derivative of the antibody; Alzheimer's disease |
| 03/21/2006 | US7014846 polyallylamine hydrochloride crosslinked with epichlorohydrin; phosphate removal from gastrointestinal tract; hyperphosphatemia; side effect reduction |
| 03/21/2006 | US7014845 copolymer of a polysaccharide and a vinyl or acrylic polymer crosslinked with a diamine, amino acid or polypeptide; sustained release; as the polysaccharide is degraded by intestinal bacteria, an active steroidal or nonsteroidal drug is released for effective absorption |
| 03/21/2006 | US7014841 Delivery of antiemetics through an inhalation route |
| 03/21/2006 | US7014840 heating a thin coating to form a vapor then allowing to cool to form a condensation aerosol; kits |
| 03/21/2006 | US7014838 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 03/21/2006 | CA2520337A1 Medicinal cooling emulsions |
| 03/21/2006 | CA2443314C Method of imaging cell death in vivo |
| 03/21/2006 | CA2443214C Vaccine composition comprising human papilloma virus 16 l1 virus-like particle (hpv 16 l1 vlp), human papilloma virus 18 l1 virus-like particle (hpv 18 l1 vlp) and 3-de-o-acylatedmonphosphoryl lipid a (3d-mpl) and alum |
| 03/21/2006 | CA2369715C Fast-dispersing dosage forms containing fish gelatin |
| 03/21/2006 | CA2339177C Thermally-inhibited starch prepared with oligosaccharides |
| 03/21/2006 | CA2258159C Intraorally rapidly disintegrable tablet |
| 03/21/2006 | CA2189863C Mucoadhesive emulsions containing cyclodextrin |
| 03/21/2006 | CA2135535C Medicinal formulations containing thioctic acid or dihydrolipoic acid in the form of inclusion compounds with cyclodextrins or cyclodextrin derivatives and in the form of granulates, chewable or effervescent tablets |
| 03/16/2006 | WO2006029150A2 Endogenously-formed conjugate of albumin |
| 03/16/2006 | WO2006029089A2 Tetrahydrocannabinoid- protein conjugates for the production of antibodies for the detection of tεtrahydrocannabinoid components in saliva |
| 03/16/2006 | WO2006028632A1 Aspartame and citrate flavored phosphate salt laxative |
| 03/16/2006 | WO2006028361A1 Implants and microspheres for the sustained release of drugs for ophthalmic use and preparation methods thereof |
| 03/16/2006 | WO2006028270A1 Rebamipide preparation for rectal administration to be prepared before using |
| 03/16/2006 | WO2006028129A1 Medicinal preparation |
| 03/16/2006 | WO2006028110A1 Process for producing water-soluble hyaluronic acid modification |
| 03/16/2006 | WO2006027711A2 Prodrugs and codrugs containing bio- cleavable disulfide linkers |
| 03/16/2006 | WO2006027685A2 Glycosylceramide adjuvant for saccharide antigens |
| 03/16/2006 | WO2006027278A1 Testosterone gels comprising propylene glycol as penetration enhancer |
| 03/16/2006 | WO2006027124A1 Pharmaceutical composition |
| 03/16/2006 | WO2006027116A2 P277 peptide formulations or variants thereof having optimised stability |
| 03/16/2006 | WO2006026829A1 Stable paste composition of enteric coated acid labile active agent and use thereof |
| 03/16/2006 | WO2005115441A3 Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| 03/16/2006 | WO2005106488A3 Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2) |
| 03/16/2006 | WO2005105070A3 Therapeutic antimicrobial compositions and methods |
| 03/16/2006 | WO2005094891A3 Method for solubilising peptide mixtures |
| 03/16/2006 | WO2005084361A3 Multi-component biological transport systems |
| 03/16/2006 | WO2005082942A3 Hydroxyethyl starch |
| 03/16/2006 | WO2005082781A3 Method for preparing adjustably bioresorbable sol-gel derived sio2 |
| 03/16/2006 | WO2005072679A3 Adjuvant formulation containing an oily emulsion with jojoba oil |
| 03/16/2006 | WO2005070468A3 Transglutaminase mediated conjugation of peptides |
| 03/16/2006 | WO2005046561A3 Multilayer dosage form comprising a matrix that influences release of a modulatory substance |
| 03/16/2006 | WO2004033663A3 Carbohydrate-based synthetic vaccines for hiv |
| 03/16/2006 | WO2004016733A3 Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| 03/16/2006 | US20060058736 Novel vaccine |
| 03/16/2006 | US20060058552 Solid preferably with an aspect ratio of 1 to 4 and a solubility in water at room temperature of at least 425 mg/ml. |
| 03/16/2006 | US20060058541 Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof |
| 03/16/2006 | US20060058513 Oxime conjugates and methods for their formation and use |
| 03/16/2006 | US20060058506 Synthetic anti-candida albicans oligosaccharide based vaccines |
| 03/16/2006 | US20060058413 Using crosslinked, porous vinylimidazole-divinylbenzene copolymers formed by specific radical suspension polymerization of a monomer mixture in presence of air and/or oxygen, a salt, and inert substance; biocompatible; removing free and albumin-bound toxins, drugs, bilirubin, and/or bile acids |
| 03/16/2006 | US20060058399 Emulsion preconcentrates containing cyclosporin or a macrolide |
| 03/16/2006 | US20060058381 Pharmaceutical formulation comprising (r)-bicalitamide |
| 03/16/2006 | US20060058378 reducing neovascularization by administering mixture of acid such as citric acid, ascorbic acid |
| 03/16/2006 | US20060058333 Analgesic compositions containing buprenorphine |
| 03/16/2006 | US20060058332 sublingual administration of N-cyclopropylmethyl-7 alpha -[1-(S)-hydroxy-1,2,2-trimethylpropyl]6,14-endoethano-6,7,8,14-tetrahydro-nororipavine, in combination with naloxone, naltrexone or nalmefene; synergistic mixtures for the treatment of pain in humans or animals |
| 03/16/2006 | US20060058279 Topical compositions comprising ascomycins |
| 03/16/2006 | US20060058277 Use of oculosurface selective glucocorticoid in the treatment of dry eye |
| 03/16/2006 | US20060058252 Methods and materials for treating human papillomavirus infections |
| 03/16/2006 | US20060058251 Use of immunostimulatory nucleic acids containing unmethylated CpG dinucleotide sequences to treat viral infections; use with viral antigen in vaccine or without a viral antigen |
| 03/16/2006 | US20060058228 nine amino acid, disulfide-constrained peptide that selectively bound and was internalized into colon cancer cells; exhibit decreased or a substantially nonexistent immunogenicity in an in vivo system |
| 03/16/2006 | US20060058220 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| 03/16/2006 | US20060057636 Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins |
| 03/16/2006 | US20060057225 Stable pharmaceutical composition useful for treating gastrointestinal disorders |
| 03/16/2006 | US20060057220 Fine spherical particles with satisfactory molecular orientation, spherical microcapsules comprising the same and processes for producing these |
| 03/16/2006 | US20060057219 Method for preparing a polymer micelle pharmaceutical preparation containing drug for injection |
| 03/16/2006 | US20060057218 N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias |
| 03/16/2006 | US20060057210 for oral administration, reducing the range in daily dosages required to control pain in human patients; specified mean maximum plasma concentration |
| 03/16/2006 | US20060057201 Multicomponent pharmaceutical dosage form |
| 03/16/2006 | US20060057195 Stable solid preparations |
| 03/16/2006 | US20060057188 Dietary supplement energy-providing to skeletal muscles |
| 03/16/2006 | US20060057187 Emulsions containing unsaturated fatty acids and esters thereof |